152 related articles for article (PubMed ID: 23880604)
1. Highlights in advanced prostate cancer from the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Clin Adv Hematol Oncol; 2013 Apr; 11(4 Suppl 7):1-22. PubMed ID: 23880604
[No Abstract] [Full Text] [Related]
2. Highlights in prostate cancer from the 2011 American Urological Association Annual Meeting and the 2011 American Society of Clinical Oncology Annual Meeting.
Yu EY
Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 21):1-24. PubMed ID: 22362073
[No Abstract] [Full Text] [Related]
3. Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal.
Gourdin T
Curr Opin Oncol; 2021 May; 33(3):252-256. PubMed ID: 33818543
[TBL] [Abstract][Full Text] [Related]
4. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
[TBL] [Abstract][Full Text] [Related]
5. Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary.
George DJ
Clin Adv Hematol Oncol; 2014 Apr; 12(4 Suppl 11):12-6. PubMed ID: 24870260
[No Abstract] [Full Text] [Related]
6. Oligometastatic prostate cancer: The game is afoot.
Lancia A; Zilli T; Achard V; Dirix P; Everaerts W; Gomez-Iturriaga A; Ingrosso G; Liefhooghe N; Miralbell R; Siva S; Van der Eecken K; Ost P
Cancer Treat Rev; 2019 Feb; 73():84-90. PubMed ID: 30684842
[TBL] [Abstract][Full Text] [Related]
7. Highlights in metastatic colorectal cancer from the 2013 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Clin Adv Hematol Oncol; 2013 Apr; 11(4 Suppl 8):1-21. PubMed ID: 23880653
[No Abstract] [Full Text] [Related]
8. Inside the 2015 ASCO Genitourinary Cancers Symposium.
Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
[TBL] [Abstract][Full Text] [Related]
9. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Shore ND
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):17-9. PubMed ID: 27167847
[No Abstract] [Full Text] [Related]
10. Metastatic prostate cancer in 2015: The new and the old that is new again.
Graff JN; Beer TM
Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
[No Abstract] [Full Text] [Related]
11. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
12. Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations.
Dellis A; Zagouri F; Liontos M; Mitropoulos D; Bamias A; Papatsoris AG;
Cancer Treat Rev; 2019 Feb; 73():54-61. PubMed ID: 30623865
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].
Omlin A; Spahn M; Beyer J; Eberli D; Gillessen S; Jochum W; Kueng M; Nitzsche E; Rentsch CA; Roggero E; Schmid HP; Stenner F; Templeton AJ; Wild D; Wyler S; Zwahlen D; Cathomas R
Praxis (Bern 1994); 2018 Sep; 107(19):1043-1051. PubMed ID: 30227804
[No Abstract] [Full Text] [Related]
14. [Androgen receptor variants in prostate cancer].
Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
[TBL] [Abstract][Full Text] [Related]
15. Highlights in advanced prostate cancer from the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Clin Adv Hematol Oncol; 2022 Apr; 20 Suppl 8(4):1-24. PubMed ID: 35579592
[No Abstract] [Full Text] [Related]
16. Highlights in prostate cancer from the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Clin Adv Hematol Oncol; 2024 Apr; 22(3):112-113. PubMed ID: 38588269
[No Abstract] [Full Text] [Related]
17. [Criteria and endpoints in advanced prostate cancer].
Piedbois P; Buyse M
Bull Cancer; 2012 Jul; 99 Suppl 1():S16-20. PubMed ID: 22511187
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatments for recurrent prostate cancer.
Hanna C; Jones RJ
Future Oncol; 2015; 11(21):2873-80. PubMed ID: 26436556
[TBL] [Abstract][Full Text] [Related]
20. Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.
Fernandez-Gomez JM; Eiro N; García-Rodríguez JJ; Quintás-Blanco A; Gonzalez-Ruiz de León C; Perez de Haro ML; Vizoso-Piñero F
Actas Urol Esp; 2017; 41(6):376-382. PubMed ID: 28161070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
